Burlington vs Roche: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Burlington and Roche side by side

1. 1896Roche

   F. Hoffmann-La Roche Founded in Basel

   Fritz Hoffmann-La Roche founds the enterprise in Basel, Switzerland, pioneering mass-manufactured, chemically standardized prescription pharmaceuticals.

2. 1898Roche

   Commercial Breakthrough with Sirolin

   Roche launches non-prescription cough syrup Sirolin, achieving widespread international distribution and financing early clinical laboratories.

3. 1934Roche

   First Industrial Synthesis of Vitamin C

   Roche becomes the first company to mass-produce synthetic Vitamin C (Redoxon) at industrial scale, anchoring decades of high-margin global cash flow.

4. 1963Roche

   Launch of Valium (Diazepam)

   Roche introduces Valium, which becomes the world's most widely prescribed psychotropic medication and establishes global pharmaceutical leadership.

5. 1968Roche

   Establishment of Roche Diagnostics

   Roche launches its dedicated diagnostic division, laying the foundation to become the world's preeminent in-vitro diagnostics (IVD) provider.

6. 1972Burlington

   Burlington Coat Factory opens

   Monroe Milstein bought a coat outlet in a former factory building in Burlington, New Jersey, and sold brand-name coats at discount prices, the start of Burlington Coat Factory.

7. 1983Burlington

   First public offering

   Burlington Coat Factory Warehouse Corporation went public for the first time, funding expansion from a regional discounter into a national chain with year-round apparel, shoes, baby and home departments.

8. 1989Burlington

   Cohoes Specialty Stores acquired

   Burlington bought the Cohoes Specialty Stores off-price chain from upstate New York, including a 50 percent stake in the Cohoes Commons building; a few stores still traded as Cohoes Fashions decades later.

9. 2006Burlington

   Bain Capital takes Burlington private

   Bain Capital acquired Burlington Coat Factory for about $2.06 billion, ending 34 years of Milstein family control. Long-time executive Mark Nesci became chief executive.

10. 2008Burlington

    Tom Kingsbury named CEO

    Former Kohl's executive Thomas Kingsbury became president and CEO in December 2008, succeeding Mark Nesci, and began overhauling buying, inventory management and the supply chain.

11. 2008Roche

    Severin Schwan becomes CEO

    Severin Schwan became CEO of F. Hoffmann-La Roche in 2008. Led Roche for 14 years; handed over to Thomas Schinecker in March 2023 and became chairman.

12. 2009Roche

    Full Acquisition of Genentech for $46.8 Billion

    Roche completes its historic $46.8 billion buyout of American biotechnology pioneer Genentech, securing market leadership in oncology biologics.

13. 2013Burlington

    Return to the stock market

    Burlington Stores priced its IPO on October 2, 2013, selling 13.3 million shares at $17 each for about $226 million, and listed under the ticker BURL.

14. 2018Roche

    Foundation Medicine & Flatiron Health Acquisitions

    Roche acquires Foundation Medicine and Flatiron Health, integrating real-world oncology data analytics and genomic profiling into personalized healthcare.

15. 2019Burlington

    Michael O'Sullivan becomes CEO

    Former Ross Stores president and COO Michael O'Sullivan succeeded Tom Kingsbury as CEO around September 16, 2019, and later launched the Burlington 2.0 plan of leaner inventories and smaller stores.

16. 2020Burlington

    Online sales end and stores close for the pandemic

    On March 5, 2020, Burlington said it would shut its e-commerce business. Days later pandemic lockdowns closed its stores, and fiscal 2020 revenue fell to $5.76 billion with a $216.5 million net loss.

17. 2023Burlington

    Bed Bath & Beyond leases

    Burlington won 44 Bed Bath & Beyond leases for $12 million at the June 2023 bankruptcy auction, the largest share of the 109 sold, and later reported 62 former Bed Bath & Beyond leases in total.

18. 2023Roche

    Acquired Telavant

    F. Hoffmann-La Roche acquired Telavant for $7.1 billion. Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.

19. 2025Burlington

    Joann leases

    After Joann's second bankruptcy, Burlington agreed in April 2025 to take over 45 Joann store leases, many of which became part of its fiscal 2026 opening program.

20. 2025Roche

    Group Sales Reach CHF 61.5 Billion

    Under CEO Thomas Schinecker, Roche delivers group sales of ~$73.8 billion (CHF 61.5 billion), driven by ~$57.2B (CHF 47.7B) in Pharmaceuticals and ~$16.6B (CHF 13.8B) in Diagnostics.

21. 2026Burlington

    Record fiscal 2025 results

    Burlington reported fiscal 2025 total revenue of $11.57 billion and net income of $610.2 million, and ended the year on January 31, 2026, with 1,212 stores.

22. 2026Burlington

    Tariff refunds put into prices

    In the second quarter of fiscal 2026, sales rose 11 percent to $2.998 billion. Burlington received $55 million in tariff refunds and said it would reinvest them in lower prices; the store count reached 1,287.

23. 2026Burlington

    Headquarters move to Philadelphia announced

    On September 3, 2026, Burlington said it will invest $370 million to move its headquarters from Burlington Township, New Jersey, to Schuylkill Yards in Philadelphia, in phases from late 2028 or early 2029.

Acquisitions

Questions about Burlington vs Roche